An Exploratory Study of the Effect of Treatment Interruption on Safety of Exenatide in Patients With Type 2 Diabetes.

Next Previous
Trial Profile

An Exploratory Study of the Effect of Treatment Interruption on Safety of Exenatide in Patients With Type 2 Diabetes.

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Jul 2014

At a glance

  • Drugs Exenatide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Sponsors Amylin Pharmaceuticals; Bristol-Myers Squibb

    • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 19 Jun 2009 Planned number of patients changed from 50 to 58 as reported by ClinicalTrials.gov.
    • 19 Jun 2009 Actual end date (Apr 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top